Compass Therapeutics, Inc.

NasdaqCM:CMPX Stock Report

Market Cap: US$335.0m

Compass Therapeutics Past Earnings Performance

Past criteria checks 0/6

Compass Therapeutics has been growing earnings at an average annual rate of 0.09%, while the Biotechs industry saw earnings growing at 31.9% annually. Revenues have been growing at an average rate of 49.1% per year.

Key information

0.094%

Earnings growth rate

28.63%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate49.11%
Return on equity-36.56%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jan 20

Compass Therapeutics: Exciting Clinical Updates Inbound For 2026

Summary Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig’s early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX’s cash runway extends into 2028, supporting continued clinical progress and mitigating near-term financing risk. Phase 1 data are preliminary; significant clinical and execution risks remain, and a better entry point may emerge if enthusiasm wanes. Read the full article on Seeking Alpha
Analysis Article • Sep 28

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jun 05

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 13

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 20

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 11

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Compass Therapeutics (NASDAQ:CMPX) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its monoclonal antibody CTX-471 in combination with cancer drug Keytruda in a phase 1b study. As per the deal, CMPX will be the study sponsor while MRK will provide the clinical supply of Keytruda. The companies will form a joint development committee to review the clinical trial results, CMPX said in a statement. The combination arm of the early-stage trial will enroll patients with non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer that have progressed after treatment with a PD-1 or PD-L1 inhibitor. CMPX stock +1.8% to $2.89 in premarket trading, while shares of MRK +0.2% to $90.65.

Revenue & Expenses Breakdown

How Compass Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:CMPX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-681956
31 Dec 250-661756
30 Sep 250-661655
30 Jun 250-621751
31 Mar 251-551746
31 Dec 241-491542
30 Sep 241-481542
30 Jun 241-471442
31 Mar 240-451241
31 Dec 230-421238
30 Sep 230-411236
30 Jun 230-431237
31 Mar 230-401232
31 Dec 220-391230
30 Sep 220-411230
30 Jun 220-351223
31 Mar 220-821120
31 Dec 210-821120
30 Sep 210-781115
30 Jun 210-811316
31 Mar 210-311316
31 Dec 200-291315
30 Sep 200-281214
30 Jun 200-27916
31 Mar 200-301119
31 Dec 190-351222

Quality Earnings: CMPX is currently unprofitable.

Growing Profit Margin: CMPX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CMPX is unprofitable, but has reduced losses over the past 5 years at a rate of 0.09% per year.

Accelerating Growth: Unable to compare CMPX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43%).

Return on Equity

High ROE: CMPX has a negative Return on Equity (-36.56%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 07:51
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Compass Therapeutics, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.